Technology | March 04, 2009

Gore Recognized as One of World’s Most Innovative Companies

March 4, 2009 - W. L. Gore & Associates has earned a spot on Fast Company magazine’s 2009 “Fast 50” list of the world’s most innovative companies, partly for its development of the GORE HELEX Septal Occluder.

Gore is ranked number 30 and appears in the magazine’s March issue.

Fast Company magazine highlights Gore’s Medical Products Division, which has provided creative therapeutic solutions to complex medical problems for three decades. During that time, more than 25 million innovative Gore medical devices have been implanted. The Gore Medical family of products includes vascular grafts, endovascular and interventional devices, surgical meshes for hernia repair, soft tissue reconstruction, staple line reinforcement and sutures for use in vascular, cardiac and general surgery.

One such device referred to in the “Fast 50” list was the GORE HELEX Septal Occluder for the treatment of atrial septal defect (ASD), a congenital heart defect that affects thousands of patients every year. The GORE HELEX Septal Occluder is the first device of its kind to use ePTFE, a biocompatible material that allows progressive tissue ingrowth, to help seal the defect. Approved by the FDA in 2006, the device is permanently implanted in a minimally invasive procedure through a catheter-based delivery system for the treatment of ASD. In December 2008, the GORE HELEX Septal Occluder became part of an FDA-approved clinical study designed to demonstrate the safety and effectiveness of the device for Patent Foramen Ovale (PFO) closure in patients with a PFO and history of cryptogenic stroke.

For more information: www.goremedical.com, www.FastCompany.com

Related Content

Videos | Structural Heart Occluders | November 08, 2017
John Rhodes, M.D., co-director of the adult congenital heart program, Medical University of South Carolina, is the pr
Videos | Structural Heart Occluders | September 13, 2017
Ziyad Hijazi, M.D., MPH, MSCAI, FACC, director of the cardiac program and chair of the Department of Pediatrics at Si
University of Alabama at Birmingham, Amplatzer PFO Occluder, first implementation
News | Structural Heart Occluders | February 15, 2017
Doctors at the University of Alabama at Birmingham have implemented the first U.S. Food and Drug Administration (FDA)-...
Amplatzer PFO Occluder, St. Jude Medical, Baylor Heart and Vascular Services, Fort Worth, Texas, first patients
News | Structural Heart Occluders | February 01, 2017
Baylor Heart and Vascular Services at Fort Worth in November became the first program in Texas to implant the Amplatzer...
RESPECT trial, Amplatzer PFO Occluder, St. Jude Medical, TCT 2016
News | Structural Heart Occluders | November 02, 2016
St. Jude Medical Inc. announced the long-term data from RESPECT, a landmark trial, during a First Report session at the...
St. Jude Medical, Amplatzer PFO Occluder, FDA approval, U.S. launch
Technology | Structural Heart Occluders | November 02, 2016
St. Jude Medical Inc. announced this week the U.S. Food and Drug Administration (FDA) approval and launch of the...
PFO closure, patent foramen ovale, AAN recommendation, American Academy of Neurology, stroke patients
News | Structural Heart Occluders | August 08, 2016
Updated recommendations from the American Academy of Neurology (AAN) states that catheter-based closure should not be...
Videos | Structural Heart Occluders | June 16, 2016
This is an animation, supplied by Gore, demonstrated how the Cardioform Septal Occluder is implanted for the transcat
PFO occluder, amplatzer
Feature | Structural Heart Occluders | May 27, 2016 | Dave Fornell
May 27, 2016 — A U.S.
Videos | Structural Heart Occluders | November 05, 2012
Positive results from the RESPECT trial of transcatheter PFO vs.
Overlay Init